Gå videre til innhold

Pressemelding -

A new clinical trial shows that daily intake of Calanus® Oil improves cardiac function and insulin sensitivity

In a recent study, a research team from The Academy of science at ​Charles University and the Czech Republic University Hospital Kralovske Vinohrady in Prague has obtained exciting results on heart function and insulin sensitivity in senior women combining physical exercise with​ Calanus® Oil supplementation.

51 women (age 65- 80, BMI 25-30) took part in a 16-week fitness program under supervision (3 exercise bouts per week). The participants were divided in two groups, one receiving a daily dose of Calanus® Oil(equivalent of 230 mg EPA and DHA), while the other (control) received sunflower oil (placebo). The study was randomized and blinded.

"The results of the study in Prague are very promising and show that regular intake of Calanus® Oil combined with physical activity leads to increased cardiac function," says CTO in ​Calanus Dr. Kurt Tande.

The hearts of the participants who took Calanus® Oil, in addition to the exercise program, showed significantly improved heart function. Both cardiac output and maximum stroke volume showed an increase of 7-8%. No improvements in cardiac performance were observed in the group that combined exercise with placebo.

Tande explains that the improvement in heart parameters can be understood as an improvement in the heart's working capacity, but also indicate lower resistance in the peripheral vascular system - and thereby better filling of the heart in its resting phase (diastole).

The aging process in humans is also associated with development of insulin resistance, which can develop into diabetes. The Prague study also shows that supplementation of Calanus® Oil in combination with physical activity leads to improved insulin sensitivity.

“Measuring insulin sensitivity in muscles by modern glucose clamp technology is demanding, but we are confident, using this gold standard technique, that supplementation with the novel marine oil from Calanus finmarchicus has a health benefit when it comes to insulin sensitivity”, says Dr. Michaela Siklova, the principal investigator of EXODYA.

The results are now being collected in a paper, which is about to be submitted for publication in a peer reviewed journal.

Both the research group in Prague, as well as the company Calanus, note that the results are in harmony with earlier preclinical findings from ​UiT The Arctic University of Norway”, says Kurt Tande.

For further information please contact Kurt Tande on tel.+47 473 82 272 or by e-mail: kurt.tande@calanus.no or Head of Sales and Marketing Jan Erik Olsen on tel. +47 951 45 351 or by e-mail: jan.erik.olsen@calanus.no. Please also refer to the company's website: www.calanus.no.

Related links

Emner

Kategorier


Calanus As is a biomarine company pioneering harvesting and utilization of the crustacean Calanus finmarchicus, and is well positioned to play a key role in industrialization of the entire value chain for through its intellectual property rights. Calanus As develops functional health- and nutrition ingredients for humans and animals exclusively from this valuable raw material. The Company’s main product is Calanus® Oil, an ecologically sustainable marine oil for humans. Calanus® Oil has unique composition and has shown benefits like improved insulin sensitivity, reduced deposition of intra-abdominal fat and powerful anti-inflammatory effects.

Kontakter

Relatert innhold

  • Calanus develops innovative zooplankton harvesting technology

    Calanus As has taken a new step towards an emerging technology development targeting oceanic harvesting of Calanus finmarchicus- the number one source of omega-3.
    Norway, Tromsø, October 24, 2019
    Harvesting of Calanus finmarchicus in oceanic waters gained momentum ensuing Norwegian Government's decision in 2019 to open up for commercial harvesting of Calanus finmarchicus. A total annual quo

  • PRESS RELEASE: Calanus As invests in a new production facility

    The decision has been triggered by the Government's decision to open for commercial harvesting of Calanus finmarchicus and the increasing demand for the company's products.
    Tromsø, Norway, June 4, 2019.
    Calanus AS is a Norwegian biomarine company pioneering harvesting and utilization of the copepod Calanus finmarchicus. The company has developed the entire value chain for sustainable harvest

  • PRESS RELEASE: Norway opens for commercial harvesting of zooplankton

    Tromsø, Norway, April 1st 2019.
    The Norwegian Government has decided to open for commercial harvesting of Calanus finmarchicus, the small copepod that constitutes the largest renewable and harvestable resource in the Norwegian sea.
    Based on a precautionary approach, the quota has initially been set at 254 000 tons per year, which is significantly lower than the potential sustainable yield.<

  • PRESS RELEASE: First Review Article on Health Effects of Wax Ester Omega-3s

    A recent review article by Schots et al., published in Frontiers in Pharmacology, investigates how the different constituents of Calanus® Oil can contribute to the prevention of obesity-induced low-grade inflammation and the associated metabolic disturbances. Calanus® Oil is a natural oil derived from the 1-year copepod Calanus finmarchicus. In addition to having the unique wax ester form, Calanus

  • Norway files application to include Calanus Oil in Codex Alimentarius

    Norwegian Authorities, represented by the Norwegian Food Safety Authority, have submitted an application to the Codex Alimentarius Commission to include calanus oil in the Codex Standard (CODEX STAN 329-2017). Codex Alimentarius is a joint initiative from The Food and Agriculture Organization and World Health Organization, both organizations from the United Nations.
    Oil from Calanus finmarchicu